All Posts Tagged With: "TRBN"
(TRBN) Trubion Pharmaceuticals Trims Size of Quarterly Loss
Trubion Pharmaceuticals Inc. (TRBN) posted a loss of 28 cents per share during the second quarter of 2010, narrower than the Zacks Consensus Estimate for a loss of 34 cents and also narrower than the year-ago loss of 37 cents. Higher revenues earned during the quarter helped...
23Aug2010 | vitalstocks | 0 comments | Continued(TRBN) Trubion Pharmaceuticals’ Loss is Wider Than Expected
Trubion Pharmaceuticals, Inc.’s (TRBN) fourth quarter fiscal 2009 net loss per share came in at 29 cents, wider than the Zacks Consensus Estimate by 10 cents. The year-ago loss was 36 cents. The year-over-year decline in loss for the reported quarter was attributable to higher...
23Mar2010 | vitalstocks | 0 comments | Continued(FACT) Facet Biotech Rejects Biogen Idec Again
Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month,...
11Dec2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation
Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech...
20Oct2009 | vitalstocks | 0 comments | Continued(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer
In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet...
12Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech
After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash...
24Sep2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Maintains Facet Biotech Offer
Yesterday, Biogen Idec (BIIB) reiterated its intention to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, even though Facet turned down the offer saying it was not in the best interests of its shareholders. The offer price represents a 64% premium...
9Sep2009 | vitalstocks | 0 comments | Continued(TRBN) Trubion Pharmaceuticals & Facet Biotech to Jointly Develop and Market Leukemia Drug
On Friday, Trubion Pharmaceuticals, Inc. (TRBN) agreed to jointly develop and commercialize TRU-016 globally with Facet Biotech Corp. (FACT). TRU-016 is undergoing early-stage studies for chronic lymphocytic leukemia (CLL). The deal requires Facet to make a $20 million upfront...
31Aug2009 | vitalstocks | 0 comments | Continued